About Richard Kuntz
Richard Kuntz, known as Rick, is an interventional cardiologist and medical technology executive. He joined the board of Elucid, a Boston company that makes AI software to read plaque in heart and neck arteries on CT scans, in July 2025. He also sits on the board of Cognito Therapeutics, a Cambridge, Massachusetts company that develops neurotechnology therapies for Alzheimer's disease. He joined that board in March 2023.
Kuntz was senior vice president and chief medical and scientific officer of Medtronic. Before Medtronic, he founded the Harvard Clinical Research Institute, a university-based contract research organization that coordinates government and industry clinical trials, and served as its chief scientific officer. He was an associate professor of medicine at Harvard Medical School, chief of the division of Clinical Biometrics, and an interventional cardiologist at Brigham and Women's Hospital in Boston. He has directed several multicenter clinical trials and written more than 250 original publications.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Richard Kuntz in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Richard Kuntz works with at each company, as listed on that company's latest Form D.
Richard Kuntz in the News
Sources
- SECElucid Bioimaging Inc. Form D/A, filed Oct 27, 2026
- SECCognito Therapeutics Group, Inc. Form D, filed Apr 1, 2025
- PressElucid names Richard E. Kuntz and Shamiram Feinglass board directors (July 17, 2025)
- PressCognito Therapeutics Series B release naming him to its board (Business Wire, March 22, 2023)
- Company siteAbout page on upstreamtechnologies.us (a different Rick Kuntz)